Key result
Ten-phospholipid biomarker panel identifies depression in CAD patients with an AUC of ~0.84.
Why the study?
Aberrant phospholipid metabolism may be an etiological mechanism linking coronary artery disease and depression, but specific phospholipid biomarkers have not been identified.
Does a specific phospholipid biomarker panel discriminate between CAD patients with and without significant depressive symptoms?
RCT (n=86)
Does a specific phospholipid biomarker panel discriminate between CAD patients with and without significant depressive symptoms?
A specific panel of 10 proinflammatory phospholipid species can accurately identify the presence of significant depressive symptoms in patients with coronary artery disease.
Answers are grounded in this paper and cite their sources.
May identify depressive symptoms in CAD; hypothesis-generating and requires prospective validation before any clinical use.
Background Depression in patients with coronary artery disease ( CAD ) is associated with increased cardiovascular morbidity. Given the proinflammatory actions of phospholipids, aberrant phospholipid metabolism may be an etiological mechanism linking CAD and depression. Our primary objective was to identify a phospholipid biomarker panel that characterizes CAD patients with significant depressive symptoms from those without. Methods and Results We performed a targeted lipidomic analysis on CAD patients with significant depressive symptoms (n=37, Center for Epidemiologic Studies Depression score ≥16) and those without (n=49). Phospholipid species were selected using partial least‐square discriminant analysis, and the ability of the resulting model to discriminate between groups was evaluated using receiver operator characteristic curves. Biosignature scores were calculated from this model, and analyses of covariance were performed to compare intergroup differences in biosignature scores, with adjustment for clinical differences between patients. Those with significant depressive symptoms had lower cardiopulmonary fitness, more prevalent history of depression, and a greater number of vascular risk factors. A model of 10 phospholipid species had an area under the curve value of 0.84 (95% confidence interval 0.72‐0.95), sensitivity of 0.73, and specificity of 0.71. This model passed permutation testing (n=1000, P <0.001). Biosignature scores were higher in those with significant depressive symptoms after adjustment for potential confounders (F[1.86]=14.39, P <0.0005). Conclusions The present findings support the role of proinflammatory phospholipid species in the presence of depression in CAD patients from the CAROTID trial (Coronary Artery Disease Randomized Omega‐3 Trial in Depression). Future investigations should aim to replicate findings in larger data sets and clarify possible pathophysiological mechanisms. Clinical Trial Registration URL : https://www.clinicaltrials.gov . Unique identifier: NCT 00981383.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2018) conducted an RCT in Coronary Artery Disease (n=86). Significant depressive symptoms vs. No significant depressive symptoms was evaluated on Discrimination between groups using a model of 10 phospholipid species (AUC 0.84, 95% CI 0.72-0.95, p=<0.001). A 10-phospholipid species model discriminated CAD patients with significant depressive symptoms from those without (AUC 0.84; 95% CI 0.72-0.95; sensitivity 0.73; specificity 0.71; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: